11:26 AM
 | 
Dec 21, 2018
 |  BC Week In Review  |  Company News  |  Deals

Amgen adds stroma-targeted therapy via Molecular Partners deal

Through a deal with Molecular Partners AG (SIX:MOLN) giving it rights to programs targeting the tumor stroma, Amgen Inc. (NASDAQ:AMGN) will expand its immuno-oncology toolbox beyond tumor antigen-targeted therapies.

On Dec. 19, Amgen received exclusive, worldwide rights to develop and commercialize tumor stroma-targeted MP0310 from Molecular Partners for $50 million up front and up to $497 million in development,...

Read the full 272 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >